New combo aims to wipe out returning nose cancer with chemo, immunotherapy, and surgery
NCT ID NCT07129772
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tests whether giving pembrolizumab (an immunotherapy) plus chemotherapy before surgery, followed by maintenance pembrolizumab, can improve outcomes for people with locally recurrent nasopharyngeal carcinoma. About 53 participants will receive up to 6 cycles of the drug combo, then undergo minimally invasive surgery to remove any remaining tumor, followed by a year of pembrolizumab. The main goal is to see how many patients have no cancer cells left in their surgical samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab, gemcitabine, cisplatin
- What this could lead to
- If successful, this approach could offer a chance to remove recurrent tumors completely and reduce the need for long-term immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 53 people, so results may not apply widely. There are risks from chemotherapy, surgery, and immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Clinical Oncology, Queen Mary Hospital
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a baking soda rinse tame radiation mouth sores?
- New drug duo aims to keep advanced nasopharyngeal cancer in check
- New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma
- New combo strategy aims to catch and remove leftover cancer after radiation
- New combo injection targets Hard-to-Treat head and neck tumors
- New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer